Companies / Kuwait
If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.
Hikma Bids For Local Rival
October 2007 | Company News AlertSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.
In a move that would ensure its dominance of the local pharmaceutical market, Jordan's largest drugmaker Hikma has launched a JOD116mn (US$164mn) bid to acquire rival Arab Pharmaceutical Manufacturing Company (AMP). The move validates BMI's earlier prediction that Hikma's strategy is set to focus more heavily on the branded generics segment in its home Middle East and Africa (MEA) region. The acquisition would bring AMP's range of 85 branded generics under Hikma's